{
    "symbol": "XBI",
    "slug": "xbi",
    "display_name": "XBI",
    "category": "stocks",
    "region": "US",
    "description": null,
    "url": "https://finscans.com/asset/xbi",
    "lang": "en",
    "as_of": "2026-06-04T14:29:13+00:00",
    "stats_30d": {
        "total_signals": 1,
        "bullish": 1,
        "bearish": 0,
        "neutral": 0,
        "explicit": 0,
        "inferred": 1,
        "avg_impact": 3,
        "avg_confidence": 40,
        "last_signal_at": "2026-06-04 14:05:50",
        "article_count": 1
    },
    "top_catalysts": [
        {
            "text": "Biotech IPO market recovery",
            "count": 1
        }
    ],
    "top_risk_factors": [
        {
            "text": "Sector-wide sell-off in biotech",
            "count": 1
        }
    ],
    "recent_signals": [
        {
            "signal_at": "2026-06-04 14:05:50",
            "sentiment": "Bullish",
            "impact_score": 3,
            "confidence_score": 40,
            "mention_type": "inferred",
            "timeframe": "short-term",
            "region": "US",
            "reasoning": "As a cancer drug IPO, Parabilis's listing could trigger sector rotation into biotech ETFs if demand is strong, given its oncology focus.",
            "article": {
                "title": "Parabilis Eyes $475 Million IPO on US Exchange to Fund Cancer Drug Trials",
                "url": "https://finscans.com/news/parabilis-eyes-475-million-ipo-on-us-exchange-to-fund"
            }
        }
    ]
}